Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Trastuzumab Rezetecan and Adebrelimab as Neoadjuvant Therapy for HER2-Positive Muscle-Invasive Bladder Cancer	Muscle-Invasive Bladder Cancer (MIBC)	Not yet recruiting	Phase 2	2026-06-03		NCT07624201

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
First Hospital of China Medical University	92
Harbin Medical University	42
Jilin Provincial Tumor Hospital	8
The Fourth Affiliated Hospital of China Medical University	4
Tianjin Medical University Second Hospital	50

0 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
No products are listed yet.

Clinical trials